Purple Biotech Reports Third Quarter 2026 Financial Results and Provides Business Update
IM1240 tri-specific antibody (capped-CD3x5T4xNKG2A): Investigational New Drug (IND) application submission planned during 2027, followed by a first-in-human studyIM1240 data to be presented in a plenary oral session at the 38th EORTC-NCI-AACR Symposium on November 20, 2026REHOVOT, Israel, Nov. 17…